Chronic lymphocytic leukaemia (CLL) is a heterogeneous B-cell cancer exhibiting a wide spectrum of disease courses and treatment responses. Molecular characterisation of RNA and DNA from CLL cases has led to the identification of important driver mutations and disease sub-types, but the precise mechanisms of disease progression remain elusive. To further our understanding of CLL biology we performed isobaric labelling and mass spectrometry proteomics on 14 CLL samples, comparing them with B-cells from healthy donors (HDB). Of 8694 identified proteins, ~6000 were relatively quantitated between all samples (q<0.01). A clear CLL signature, independent of subtype, of 544 significantly overexpressed proteins relative to HDB was identified, highlighting established hallmarks of CLL (eg. CD5, BCL2, ROR1 and CD23 overexpression). Previously unrecognised surface markers demonstrated overexpression (eg. CKAP4, PIGR, TMCC3 and CD75) and three of these (LAX1, CLEC17A and ATP2B4) were implicated in B-cell receptor signalling, which plays an important role in CLL pathogenesis. Several other proteins (eg. Wee1, HMOX1/2, HDAC7 and INPP5F) were identified with significant overexpression that also represent potential targets. Western blotting confirmed overexpression of a selection of these proteins in an independent cohort. mRNA processing machinery were broadly upregulated across the CLL samples. Spliceosome components demonstrated consistent overexpression (p=1.3x10 -21 ) suggesting dysregulation in CLL, independent of SF3B1 mutations. This study highlights the potential of proteomics in the identification of putative CLL therapeutic targets and reveals a subtype-independent protein expression signature in CLL.
Introduction
Chronic lymphocytic leukaemia (CLL), the most common adult leukaemia in the western world, is a CD5 + B-cell neoplasm with a heterogeneous clinical course (1, 2) . B-cell receptor (BCR) signalling plays a role in the pathogenesis of CLL and drugs targeting this pathway are revolutionising CLL treatment (3) . Indeed, the mutational status of the immunoglobulin heavy-chain variable-region gene (IGHV) within the BCR largely correlates with disease outcome. CLL cases with unmutated Vgenes (U-CLL) typically have a progressive disease with patients often requiring early treatment, in contrast cases with mutated V-genes (M-CLL) are more indolent, and those presenting with a low tumour burden often never require treatment (4) .
CLL transcriptomics analyses have identified minimal differences in gene expression between
subtypes such as U-and M-CLL suggesting that common mechanisms elicit CLL pathogenesis (5, 6) .
More recently, the DNA methylation profile of CLL cases was shown to closely reflect that of the proposed cell of origin, namely memory B-cells (MBC) and naive B cells (NBC) for M-CLL and U-CLL, respectively. Interestingly, both studies identified a third epigenetic CLL subgroup with an intermediate methylation signature enriched within M-CLL with between 95% and 98% IGHV somatic mutations. These three CLL epitypes exhibit different clinico-biological features, with the MBC-like CLL cases exhibiting a more indolent clinical course (7) (8) (9) (10) .
Although no single aberration appears to drive disease development, many recurring gene mutations and chromosome abnormalities have been described in CLL, and several have prognostic and/or predictive significance. Deletion of 17p and 11q which results in the loss of TP53, baculoviral IAP repeat-containing 3 (BIRC3) or ataxia-telangiectasia mutated serine/threonine kinase (ATM) respectively, are frequently associated with TP53 and ATM mutations on the remaining allele and poor outcome following chemo-immunotherapy (11, 12) . In contrast the most frequent cytogenetic abnormality in CLL, deletion of 13q, results in increased expression of the anti-apoptotic protein Bcl-2, largely due to loss of miRNA15 and miR16-1, and is associated with a good prognosis, particularly in M-CLL.
Other recurrent mutations also influence disease progression and treatment response. Next generation sequencing studies have confirmed that mutations of splicing factor 3B subunit 1 (SF3B1) (13) and neurogenic locus notch homolog protein 1 (NOTCH1), a transmembrane receptor and transcriptional regulator determining cell fate (14) , are the most frequent recurring mutations in CLL, with an incidence of approximately 18% and 12%, respectively, at the time of initial treatment.
Mutations in either gene are associated with a poorer outcome following chemo or chemoimmunotherapy and NOTCH1 mutations are also predictive of a poor response to chemotherapy plus anti-CD20 antibody combinations (15, 16) .
SF3B1 is a spliceosome component with a role in the regulation of pre-mRNA intron excision. Heterozygous missense mutations of the C-terminal HEAT domain are the most frequent alteration to SF3B1, impacting spliceosomal function (17) . Indeed, SF3B1 mutation has been shown to induce large numbers of aberrantly spliced and altered gene products in CLL (18) . The frequency of SF3B1 mutations and the resulting changes to spliceosomal activity suggest that dysregulation of the spliceosome plays a prominent role in CLL pathogenesis.
Liquid chromatography with mass spectrometry (LC-MS) proteomics provides an effective means of establishing global differential protein expression profiles. Several studies have previously employed MS proteomics in the analysis of CLL (recently reviewed (19, 20) ); with the latest, a characterisation of 9 U-CLL versus 9 M-CLL, identifying 3521 and relatively profiling 2024 proteins, of which approximately 100 proteins were differentially expressed (±1.5-fold change, p<0.05) (21) .
Several earlier studies provided limited proteome coverage but suggested a number of markers of poor prognosis, such as nucleophosmin, PDCD4 and TCL1 (22) (23) (24) (25) (26) (27) . Technological and methodological advances such as Orbitrap technology, isobaric labelling and two dimensional chromatography have greatly improved proteomics coverage, leading to the first comprehensive drafts of the human proteome (28) (29) (30) .
Our current discovery stage study has applied isobaric labels and LC-MS proteomics to the characterisation of isolated B-cell material from 3 healthy donors and 14 CLL patients. CLL samples were selected to include a range of clinically relevant CLL subtypes associated with poor prognosis versus healthy donor B-cells with the aim of assessing CLL-specific differential protein expression.
The resulting quantitative proteomes identified a strong signature common to CLL, highlighting several potential therapeutic targets and suggesting mechanisms, such as spliceosome overexpression, contributing to pathogenesis. (Table S1 ). Isolated cell pellets were snap frozen and stored in liquid nitrogen prior to lysate preparation.
Methods

Materials
Isolation of healthy donor and CLL B-cells from clinical samples
Experimental Design and Statistical Rationale
CLL samples were selected to include a range of clinically relevant CLL subtypes associated with poor prognosis. Samples were assigned evenly across two batches of analysed samples, to accommodate the capacity limits of the isobaric labels (Table S1 ). To simultaneously analyse and provide relative quantitative comparability of 14 CLL proteomes, samples were assigned to two tandem mass tag (TMT) 10-plex label sets. Three healthy donor B-cell (HDB) samples were used as both biological and inter-experimental bridging controls. HDB peptides were prepared and TMTlabelled prior to bifurcation and allocation to each 10-plex. The selected samples included (nondiscretely) 5 Trisomy 12 cases, 3 CD38 + (>99%) cases, 8 unmutated IGHV cases, 5 NOTCH1-mutant cases and 5 SF3B1-mutant cases (Table S1).
To minimise batch effects, reduce technical noise and disregard inconsistent observations, a stringent approach considering only the smallest of the CLL to HDB fold changes was adopted;
detailed in 'Quantitative and Statistical Analysis of MS Data' below. CLL:HDB ratios were evaluated by an FDR-corrected 1 sample t-test and compared alongside a value termed the regulation score (Rs) (31), a more robust measure than an average, also detailed below. With 14 samples, in those instances where variation was as low as 25%, a fold change of ~1.25 could be concluded, based on the power analysis calculations presented by Levin (33) . Use of standard deviation as the denominator in the regulation score adjusted for variation on a case by case basis. At a threshold of Rs>0.3, the lowest fold change defined as significantly regulated was 1.25, observed with an average variation of 18%.
Sample and Peptide Preparation and labelling for LC-MS
Snap frozen cell pellets were lysed on ice by trituration with a 23 gauge needle in 0.5 M TEAB containing 0.05% w/v SDS. Disrupted cells were further sonicated on ice and lysates cleared by centrifugation at 16,000 g for 10 minutes at 4°C. Protein concentration was determined by a Direct 
Peptide Fraction Analysis by LC-MS/MS
MS Data Processing
Target-decoy searching of raw spectra data was performed with Proteome Discoverer software version 1.4.1.14 (Thermo Scientific). Spectra were subject to a two stage search, both using PhosphoRS was used to predict the probability of specific phosphorylated residues. Reporter ion intensities were extracted from non-redundant PSMs with a tolerance of 20 ppm. Data from the two 10-plex experiments was searched separately and combined for protein grouping by Proteome Discoverer. The raw data and processed outputs have been deposited to the ProteomeXchange Consortium (33) via the PRIDE partner repository with the dataset identifier (PXD002004).
Quantitative and Statistical Analysis of MS Data
Log2 (ratios) were generated describing each CLL sample relative to the three HDB bridging controls (Table S2) . To select for only the most robust and consistent findings, the ratio of CLL:HDB control was assessed for all 3 HDB controls and, rather than a potentially misrepresentative average value, the ratio with the lowest fold change was selected. Findings with both up and downregulation for a protein amongst the 3 CLL:HDB ratios were rejected. For example: for fold-changes of 1.4, 1.5 and 1.8, 1.4 was selected; for fold-changes of -2.2, -1.7, -1.9 -> -1.7 was selected; for fold-changes of 1.5, -1.9, 1.3 -> a value of 0 was taken.
To reduce ratio compression, peptide spectrum match data for proteins (q<0.01) were exported from Proteome Discoverer and submitted to Statistical Processing for Isobaric Quantitation Evaluation (SPIQuE) at spiquetool.com. This method weighted the contributions of each PSM quantitation to a protein's quantitation on the basis of PSM features (manuscript in preparation). For example, high-intensity peptides with low isolation interference were given a greater weighting factor, as previously applied (31).
Due to the substantial differences in non-B-cells present in the HD and CLL PBMCs, contamination emerged in the HDB samples as a number of downregulated proteins. To accommodate for the contamination, the analyses primarily focused on proteins overexpressed, and therefore specifically attributable to CLL. As the most apparent source of contamination in the proteomics results were platelet-derived proteins, a filtering list consisting of the 1000 most abundant platelet proteins was generated from a prior proteomics analysis of platelets, defined by copy number (described previously (34) ). Of these 1000 proteins, 194 were observed with apparent overexpression in the HDB samples which were subsequently removed from the dataset. Additionally the WT CLL sample 4621 appeared as an outlier and was therefore excluded from further analyses.
For the minimally deviated log2 (ratios), differential expression in CLL, relative to HDB, was defined by an FDR-corrected one sample t-test, where p<0.05 and the regulation score (Rs), where Rs>0.3 or >-0.3. Rs provided a single, robust measure, representative of both the magnitude and consistency of differential expression (Rs = mean/(standard deviation +1)). For proteins with no, or inconsistent differential expression, the Rs tended towards 0.
Bioinformatics Analyses
Proteins reaching the thresholds outlined above were submitted to either Ingenuity Pathway 
Flow Cytometry
Cells were stained with either the manufacturer's recommended concentration, or 10 μg/ml, of in-house antibody for 30 minutes in the dark at 4°C, washed and analysed by flow cytometry with a FACScalibur (BD Biosciences, Franklin Lakes, New Jersey) (35, 36) .
Western Blotting
Independent cohorts of isolated B-cells and CLL cells were washed in cold PBS and lysed in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% Deoxycholate, 0.1% SDS, 50 mM Tris, pH 8).
Protein content was quantified against a BSA standard curve using a standard Bradford assay 
Results
Quantitative proteomics of CLL relative to healthy donor B-cell samples identifies a consistent, reproducible CLL phenotype
The MS and TMT workflow applied to measure relative differential expression in the proteomes of CLL cells versus HDB controls is summarised in Figure 1 . A total of 8694 proteins were identified (q<0.01) of which 5956 proteins were relatively quantified for all samples (Table S2) .
Hierarchical clustering of differential expression across the 14 CLL samples, relative to HDB, highlighted a broad CLL-specific signature with no distinctly clustered subtypes (Figure 2A,B) . The reproducibility of this signature was also apparent when comparing the average CLL expression determined in the two distinct 10-plex experiments (R 2 =0.799) and the technical reproducibility between the HDB bridging controls (R 2 =0.797) ( Figure S1) .
544 significantly overexpressed and 592 significantly underexpressed CLL proteins, relative to HDB, were identified with a regulation score of >0.3 or <-0.3, respectively (Figure 2C) . Amongst the overexpressed proteins were examples of well-characterised hallmarks of CLL; CD5, BCL2, CD23 and ROR1. 18 proteins were identified with a greater overexpression than CD5, several of which were previously undescribed in CLL (Figure 2D) .
In addition to the overexpression of CD5, BCL2, CD23 and ROR1, several other previously reported CLL protein upregulations were present in the data; including ST14/matriptase, CD6, PTPN22, CDKN1B/p27, TRAF1, JUND, BMI1, IKZF3/Aiolos, TOSO, DIABLO/SMAC and SIT1 ( Figure 3A) . Additionally overexpression was also apparent, although more variably, for CLL proteins ZAP-70 and IL4Rα.
Markers differentiating CLL subtypes were also observed by proteomics. Integrin alpha 4 (CD49d) expression was significantly higher in trisomy 12 cases as previously described (37) , IgM expression associated with U-CLL cases (3), CD38 expression was correctly identified as significantly higher in CD38 + (>99%) cases, and the Y-chromosome-encoded proteins (EIF1AY and RPS4Y1) allowed the differentiation of patient genders (Figure S1) . Subtype specific differences emerging from the proteomics were considered (Figure S3 , Table S3 ), however lacked the statistical power for significant findings.
Putative novel CLL immunophenotypes and drug targets
In addition to confirmation of established characteristics, several novel observations emerged amongst the most up-regulated proteins (Figure 2C,D) . Cytoskeleton-associated protein 4 (CKAP4), a cell surface receptor for antiproliferative factor (APF), was the most significantly and consistently upregulated CLL protein (250-590% HDB expression, p=1. were also evaluated to demonstrate the concordance between the proteomics-and Western blottingderived ratios for proteins with known over-or under-expression in CLL.
In addition to the proposed cell surface expression of CKAP4, CLL proteomics identified 20
consistently upregulated proteins annotated with surface localisation (Figure 4) . This list highlighted ATP1B1, C17orf80 and NPTN (Figure S4) , with no previous descriptions of protein upregulation in CLL, providing them as targets for future evaluation for roles in CLL biology or as bio-markers.
While for CKAP4, and to some extent PIGR, surface localisation may be affected by internalisation, other candidates, such as lymphocyte transmembrane adapter 1 (LAX1), transmembrane calcium-transporting ATPase (ATP2B4) and prolectin (CLEC17A) are likely primarily localised to the cell periphery. LAX1, ATP2B4 and CLEC17A may additionally present potential effectors of BCR signalling (39) (40) (41) (42) .
Next, overexpressed CLL proteins were annotated for their potential as therapeutic targets based on existing drug/inhibitor knowledge using IPA (Figure 5) . Both functional heme oxygenase isoforms (HMOX1 and HMOX2), which offer cytoprotective effects through free heme degradation,
were observed upregulated and annotated as targets of tin mesoporphyrin. Histone deacetylases HDAC3 and HDAC7, and to a lesser extent HDAC1 and sirtuin 5 also presented putative targets of inhibition. This list additionally contained several kinases as therapeutic targets, such as two mitogenactivated protein kinases; MAPK8/JNK1 and MAPK13; two tyrosine-protein kinase protooncoproteins; FGR and LCK; and two cell cycle progression kinases; cyclin-dependent kinase 7
(CDK7) and the G2 checkpoint kinase WEE1.
mRNA processing upregulation in CLL
Gene ontology (GO) term enrichment was used to identify over-represented features of CLL biology (Figure 6A) . Transcription and transcript processing were dominant features amongst the 544 overexpressed proteins, with 'mRNA processing' the most significantly enriched term (p=2.9x10 -48 )
with 95 annotated proteins. The majority of the most significant biological process terms additionally described mRNA-related processes. Four terms describing RNA splicing, for instance, were highly enriched (n>72 proteins, p<10 -40 ). Another emerging trend was that of chromatin modification and organisation (n>84, p<2.3x10 -23 ). Enrichment of cellular component and molecular function terms further described the dysregulation of mRNA-related processes, such as 'nucleoplasm' (n=258, p=2.1x10 -69 ), 'spliceosomal complex' (n=44, p=2.0x10 -26 ) and 'RNA binding' (n=167, p=6.0x10 -45 ).
IPA canonical pathway enrichment identified broad up-regulation of proteins and isoforms involved
in 'cleavage and polyadenylation of pre-mRNA' (p=2.0x10 -10 ) (Figure 6B) and 'pre-initiation complex assembly' (p=1.7x10 -4 ) (Figure 6C) .
Upregulated KEGG pathways were also interrogated, identifying a 9-fold enrichment of spliceosome components (n=36, p=1.3x10 -21 ) (Figure 7A) . A further 60 components were identified with marginal upregulation (0.1<Rs<0.3, p<0.05). Figure 7B presents all proteins within the quantified proteome which map to the KEGG spliceosome pathways highlighting a near-consistent trend of some degree of over-expression across the CLL samples relative to HDB.
Discussion
CLL has been the subject of numerous investigations applying genomics and transcriptomics that have contributed greatly to the clinical and biological understanding of the disease (6, 43-45).
However, low correlations observed between mRNA and protein expression limits insight from these studies (46, 47) . Indeed, a comparison between a previous transcriptomics analysis of CLL (38) and these proteomics results highlight minimally correlated differential expression ( Figure S2) .
Proteomics has been applied to CLL in a number of investigations providing insight into potential differences between subtypes and some CLL-specific signatures (21, 22, 25, 26, 48, 49) . To date, however, CLL proteomics studies have lacked sufficient coverage to identify the majority of expressed proteins and are yet to fully explore comparisons with healthy donor B-cell controls.
This study aimed to implement advances in quantitative LC-MS proteomics to provide a detailed characterisation of a broad spectrum of CLL samples and evaluate changes in protein expression relative to B-cells derived from healthy donors. Overall, this investigation provided a substantial, reproducible ( Figure S1 ) and representative (Figure 3) description of the CLL proteome to a depth of almost 6000 proteins. Additionally the accuracy of the results for individual samples was highlighted by the expression of key subtype markers (Figure S1) suggesting the potential of the presented methods for the dissection of subtype-specific differences in CLL and other cancers in the future.
The most striking finding was that of a consistent subtype-independent expression profile across the CLL samples (Figure 2B) . Given the heterogeneous clinical nature of CLL, some variation and clustering of subtypes was anticipated, although homogeneity amongst CLL subtypes has also been observed previously by transcriptomics (5, 6) . This suggests that the phenotypic differences between CLL subtypes may either be a product of post-translational modifications, microenvironment interactions or CLL niche-specific characteristics. Further studies with greater sample numbers will be required to better understand these potentially subtle differences in protein expression.
Phenotypic differences exist between CLL cells in lymph nodes and peripheral blood (50) , suggesting that evaluation of CLL cells from additional niches may be required to understand the differences in disease behaviours observed between subtypes. Furthermore, evaluation of fractionated B-cell subsets from several niches would serve as more informative controls. Indeed, given recent insights from methylation studies relating to the likely cell of origin for different CLL sub-types, B
cell subsets relevant to each CLL sample (i.e. MBC for M-CLL and NBC for U-CLL) should be evaluated, guided by their CpG methylation signatures (7) (8) (9) (10) . Currently, we are not aware of proteomics data describing these B-cell subsets.
The findings presented here provide several potential novel hypotheses for further investigation. CKAP4, for instance (Figure 2D, 3) , was robustly identified as a highly abundant, overexpressed, putative surface protein in CLL and validated in a separate cohort by Western blotting.
This offers potential mechanistic insight into CLL and presents a prospective clinical tool. In addition to roles in the endoplasmic reticulum and as a transcription factor (51), CKAP4, also known as CLIMP-63, can act as a cell surface receptor for tissue plasminogen activator (tPA) (52), surfactant protein A (SP-A) (53) and anti-proliferative factor (APF) (54) . APF treatment of a bladder cancer cell line resulted in reduced proliferation, attributable to substantially reduced phosphorylation of AKT and GSK3β and an increased expression of p53 (55) . Interestingly, substantial CKAP4 overexpression was also observed in tumours of the Eμ-TCL1 mouse model of CLL suggesting a potential means of investigation (31). Targeting CKAP4 with either ligands or immunotherapy may offer means of treating CLL.
INPP5F mRNA overexpression in CLL has previously been linked with low progression free survival for patients undergoing fludarabine-based therapy (56) . The proteomics and Western blot validation presented here indicate that the INPP5F protein is commonly overexpressed in CLL.
Together these observations suggest INPP5F may present a therapeutic target in CLL, especially in treatment-resistant cases and its mechanism in CLL warrants further investigation.
The identification of several consistently upregulated membrane proteins in CLL versus
HDBs (Figure 4, S4) highlighted the potential of proteomics approaches to identify novel immunotherapy targets for selective targeting with mAb. Additionally, identification of proteins linked with BCR signalling should enable a better understanding of this process in CLL which may enable improved therapeutic targeting of this currently incurable disease (39) (40) (41) (42) . LAX1 was shown to be phosphorylated upon BCR stimulation by Src and Syk (39) , with B-cell hyper-responsiveness observed in LAX1 -/mice suggesting a regulatory role in BCR signalling (57). ATP2B4 has a role in BCR-induced calcium efflux (40) and Prolectin, also known as CLEC17A, is expressed in germinal centre B-cells where expression correlates with proliferation (58) . Prolectin also has a potential role in BCR signalling, through an association with BLNK (42) .
The analysis of drug targets further highlighted the potential of proteomics in the identification of putative clinical tools (Figure 5) . Wee1 overexpression, for instance (Figure 3B) , suggests a potential target to inhibit the cell cycle, with the inhibitor MK1775 shown to have therapeutic benefit in other cancers (59) . The upregulation of the HMOX1 and 2 suggested an increased degradation of free heme in CLL, combined inhibition of which could induce apoptosis (60) . A trend of HDACs upregulated in these results highlighted the potential of targeted HDAC inhibitors (HDACi). Entinostat, for instance, specific to HDAC1 and HDAC3, both upregulated here, was previously identified to induce pro-apoptotic effects in CLL (61) . HDAC7 additionally exhibited consistent upregulation, observed previously at the mRNA level (62), suggesting the possibility of more targeted means of HDAC interference, with fewer off-target effects compared to those seen in previous pan-HDACi trials in CLL (62-64).
The strong signature of upregulated mRNA processes highlighted by the bioinformatics analyses ( Figure 6 ) suggests a general underlying defect in CLL, independent of sub-type. SF3B1 mutations (65) and observations of major dysregulation of splicing patterns (44) have previously indicated aberrant spliceosome activity in CLL. Additionally, inhibition of SF3B1 by spliceostatin-A was toxic to CLL independent of SF3B1 mutational status, suggesting a broader role for aberrant splicing in CLL biology (66) . The observation of broadly consistent overexpression of spliceosomal proteins (Figure 7) , may therefore offer some explanation for these previous observations. This reinforces the notion that interference with aberrant splicing activity could offer a means of better understanding and potentially treating CLL.
A limitation to our study was the observation of non-B-cell contaminants in the HDB samples resulting from the substantial difference in percentage of non-B-cells and platelets between healthy donor and CLL patient PBMCs; varying from 95% in healthy PBMCs to below 10% in CLL patient PBMCs. Emphasis was therefore placed upon overexpressed proteins in CLL and conclusions based upon downregulated proteins -potentially attributable to contamination in the HDB samplesavoided.
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